Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Manhattan Pharmaceuticals has completed patient enrollment in its ongoing Phase IIa clinical study of Topical PTH (1-34). This randomized, double-blind, vehicle-controlled, parallel group study is designed to evaluate safety and preliminary efficacy of Topical PTH (1-34) for the treatment of psoriasis.
Subscribe to our email newsletter
The study randomized 61 patients into three treatment groups (two dose levels of Topical PTH (1-34) and one vehicle only group) for an eight-week treatment period at four US clinical trial sites. The vehicle used in this study is the topical product without the active ingredient, PTH (1-34). The company expects to announce the results of this study in summer 2008.
Douglas Abel, president and CEO of Manhattan Pharmaceuticals, said: “We are pleased to have completed enrollment in this Phase IIa study on schedule. We look forward to completing the study and announcing results later this year.”